



December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2010-024396-12/ Novartis Protocol ID CBEZ235C2201

A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma

Trial CBEZ235C2201 was cancelled with no patient enrollment and as such, no results will be reported.